Kornimate/medical-research-clean huggingface dataset:
improving radical treatment through mri evaluation of pelvic sigmoid cancers

Conditions: Cancer; Colorectal Neoplasms; Colon, Sigmoid; Magnetic Resonance Imaging; General Surgery

Summary: patients with suspected or proven sigmoid colon adenocarcinoma, eligible for curative treatment whose mri can be reviewed prior to surgery and has no decision regarding radical treatment are eligible. patient are randomised to the control arm which the standard care of preoperative ct imaging and subsequent discussion by the multidisciplinary team or the interventional arm which has the additional use of mri imaging and subsequent discussion by the multidisciplinary team. patients are followed up at 1 and 3 years together with qol questionnaires.

a randomised phase ii multicentre trial, impress will determine whether the use of mri imaging in staging sigmoid cancers results in a change to the treatment plan by identifying more high risk tumours compared to those patients who were staged using ct imaging. the proposed intervention will be additional radiological and pathological assessment and the reporting of supplementary diagnostic information which would not otherwise have been available. this may affect treatment according to local mdt protocols and also affect the provision of prognostic information to patients in subsequent discussions.

Eligibility criteria:
inclusion criteria: 1. have a suspected or proven sigmoid colon adenocarcinoma 2. is eligible for curative treatment 3. has no irresectable metastatic disease 4. mri can be reviewed by an mdt prior to surgery 5. has no decision regarding radical treatment 6. have provided written informed consent to participate in the study 7. be aged 16 years or over exclusion criteria: 1. have metastatic disease (including resectable liver metastases) 2. have a synchronous second malignancy 3. are contraindicated for mri 4. are contraindicated for or have allergy to buscopan (e.g. glaucoma, small or large bowel obstruction, gfr\<30) 5. have severe co-morbidities or previous medical history that prevent the application of eventual chemo/radiotherapy

Keywords: cancer colorectal neoplasms colon, sigmoid magnetic resonance imaging general surgery postoperative complications
radiofrequency ablation assisted hepatectomy versus hepatectomy alone for advanced hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: rfa has become a standard method in the treatment of small hcc(≤2 cm) due to its ease of use, safety, cost-effectiveness, and minimal invasiveness. it can ablated and blocked the small vessels while destroyed the tumor cell in situ. surgical resection is the most widely accepted treatment for the patients with advanced hepatocellular carcinoma in the asian countries. but the effectiveness of hepatectomy was depressed because of the high recurrence rate. the spreading of the cancer cell along the portal vein or the hepatic vein system during the operation account for the tumor recurrence. using rfa to ablate and block the small vessels around the tumor before resection will reduce the spreading of the cancer cell. investigators hypothesized that the rfa assisted hepatectomy might result in lower recurrence rate than hepatectomy alone in the treatment of advanced hcc. thus, the purpose of this study was to prospectively compare the effects of rfa assisted hepatectomy with hepatectomy alone for the treatment of advanced hcc.


Eligibility criteria:
inclusion criteria: 1. diagnosis of hcc confirmed at our hospital. 2. intrahepatic tumor count no higher than 3 and a minimum tumor diameter \> 3 cm, but no more than 8cm. 3. liver function of child-pugh class a or b. 4. tumors lacked intrahepatic and extrahepatic metastasis. 5. tumors had not invaded the portal vein, the hepatic vein trunk or the secondary branches. 6. indocyanine green retention at 15 minutes (icg-15) of \<10%. 7. no evidence of coagulopathy: platelet count \> 50 × 109/l and a prolonged prothrombin time of \< 5 seconds. 8. no other anti-tumor therapy received before the treatment. - exclusion criteria: 1. patients met the inclusion criteria but declined to participate. 2. patients with severe portal hypertension, a history of esophageal variceal hemorrhage, severe hypersplenism syndrome, or refractory ascites. 3. patients whose permanent pathology after treatment suggested metastatic liver cancer or primary liver cancer of another tissue type.

Keywords: hepatocellular carcinoma radiofrequency ablation hepatectomy recurrence
safety and pharmacokinetic study of carbamylated erythropoietin (cepo) to treat patients with acute ischemic stroke

Conditions: Acute Ischemic Stroke

Summary: the primary purpose of the study is to determine whether carbamylated erythropoietin (cepo) dosed once daily for 5 days is a safe treatment for patients who have suffered an acute ischemic stroke.

acute ischemic stroke is a major cause of death and severe disability. the naturally occurring hormone, erythropoietin (epo), is able to protect various neuronal tissues from ischemic injury and is beneficial in animal models of acute ischemic stroke. lu aa24493 is a modified (carbamylated) version of epo, neuroprotective but without the haematopoietic side effects. lu aa24493 is developed for treatment of patients with acute ischemic stroke.

Eligibility criteria:
inclusion criteria: * age between 50 and 90 years * clinical diagnosis of acute ischemic stroke * measurable stroke-related deficit * patient is stable * treatment can be initiated between 0 hours and 48 hours after the onset of stroke * expected hospital stay of at least 120 hours after first dose of study medication * if female then not of childbearing potential exclusion criteria: * primary intracerebral haemorrhage (ich), or parenchymal haemorrhagic transformation of infarction (type phi or phii as defined in ecass), subarachnoid haemorrhage (sah), arterio-venous malformation (avm), cerebral aneurysm, or cerebral neoplasm * treated with a thrombolytic \ 24 hours and excluded ich then eligible) * score \>=1 on the nihss item 1a * pre-stroke mrs score \>=2 * uncontrolled hypertension * previous treatment with erythropoietin * previous exposure to lu aa24493

Keywords: acute ischemic stroke erythropoietin carbamylated neuroprotection
infectious aetiology of potentially malignant disorders and squamous cell carcinomas of the oral cavity

Conditions: Squamous Cell Carcinoma of the Oral Cavity; Leukoplakia Oral

Summary: recent studies estimated that 15 to 20% of all cancers in humans are associated with viruses. among oral cancer about 90% are oral squamous cell carcinomas (oscc). alcohol and tobacco consumption have been recognized for years as the main risk factors for development of osccs. however, 10 to 20% of patients suffering from osccs are non-smokers and/ or non-drinkers. consequently, the hypothesis of another agent responsible has risen. indeed, several studies have suggested the possibility that a virus could be associated with or be a causal agent of oscc. the first objective is to detect and characterize the presence of infectious agent (mostly virus) transcripts in pre-malignant or malignant tumours from patients with osccs.the secondary objectives are (i) to associate and (ii) if possible define a causality link between these agents and a subset of potentially malignant disorders and/or osccs.


Eligibility criteria:
inclusion criteria: * patient over 18 years, * for subgroup "potentially malignant disorder : clinical diagnosis of leukoplakia, * for subgroup "oscc" : histological diagnosis of oscc, * patient who never smoked, or light smoker, (≤5 pack-year) or 15 years of cessation, * patient who never drank, or light drinker (≤ 20 g/day for men and 10g/day for women) or 15 years of cessation, * informed consent signed. exclusion criteria: • previous treatment of oral cancer,
the occurrence of mace in patients with ami receiving pitavastatin/valsartan treatment

Conditions: Hypercholesterolemia

Summary: prospective observation study to identify the rate of mace in ami with livalo v(pitavastatin/valsartan) for 12 month in korea

following subjects with ami event within 1 month will be assessed mace event for 1year * essential hypertension or heart failure * idiopathic hypercholesterolemia (heterogeneous familial and non-familial hypercholesterolemia, fredrickson classification type iia) * mixed-type hypercholesterolemia (fredrickson classification type iib) with acute myocardial infarction (stemi, nstemi),

Eligibility criteria:
inclusion criteria: * idiopathic hypercholesterolemia (heterogeneous familial and non-familial, fredrickson type iia) or mixed-type (fredrickson type iib) with ami (stemi, nstemi), including essential hypertension or heart failure * diagnosed ami (stemi, nstemi) 1 months ago * more than 19 years old and more than 2 years of life expectancy at screening * informed consent exclusion criteria: * cardiogenic shock or corresponding clinical events * contraindicated to the ip * unsuitable to this study judged by investigators
gingival phenotype prevalence of lower incisors and associated risk factors : a cross-sectional study

Conditions: Gingival Diseases

Summary: several types of gingival phenotype can be diagnosed in the general population and their evaluation is an essential clinical criterion in periodontal practice, whether the periodontal therapies are preventive or curative, non-surgical or surgical. moreover, several authors have shown that the gingival phenotype varies from one dental sector to another, hence the interest of a meticulous and targeted diagnostic approach in relation to the established therapeutic objectives. to date, the gingival phenotype has been not studied extensively in the mandibular incisal area. therefore, it seems relevant to conduct an observational cross-sectional study on a cohort of patients in good general health and with a healthy and intact periodontium to assess the prevalence of the gingival phenotype in this area. the secondary objective is to highlight the associated intrinsic and extrinsic risk factors for thin gingival phenotype, to anticipate a risk of gingival recession and to propose an early personal therapy.


Eligibility criteria:
inclusion criteria: * age (18 years old or older) * dental student on the university hospital of nice * social security affiliate * systemically healthy * healthy and intact periodontium * informed consent. exclusion criteria: * pregnancy * under any regular medical treatment * active periodontal disease * presence of plaque * enduring orthodontic treatment * periodontal surgery in the mandibulary anterior region * non consent patient * patient under judgment trials.
tlesr-impedance study in patients

Conditions: Reflux Episodes

Summary: the purpose of the study is to compare frequency and content of reflux episodes in patients with gastroesophageal reflux disease.


Eligibility criteria:
inclusion criteria: * provision of written consent * gerd patients, age 18-70 years, females must be postmenopausal or surgically sterilised * 6 months history of gerd and incomplete response to ppi treatment exclusion criteria: * insufficient symptom burden of the reflux disease evaluated by questionnaires * s-creatinine \>1.2 times upper limit of normal * history of heart disease * prior surgery of the upper gi tract

Keywords: gerd transient lower esophageal sphincter relaxations (tlesrs) reflux
warfarin prevents portal vein thrombosis in liver cirrhotic patients with hypersplenism after laparoscopic splenectomy

Conditions: Cirrhosis; Hypertension; Venous Thrombosis; Status; Splenectomy

Summary: the purpose of this study is to determine whether warfarin anticoagulation are effective and safe in prevention of portal vein thrombosis in liver cirrhotic patients with hypersplenism after laparoscopic splenectomy.

after successful screening the cases of cirrhosis of liver irrespective of the etiology who have non tumor portal vein thrombosis will be enrolled. the baseline doppler parameter will be recorded and the patient will be randomized into either interventional (warfarin) or control (aspirin) group. from postoperative day 3, patients in interventional (warfarin) group will receive oral warfarin 2.5mg qd with titration of dose to maintain a target inr of 2-3 for 1 year, patients in control (aspirin) group will receive oral aspirin enterie ccoated tablets 100mg qd for 1 year, and both groups will be along with five days of subcutaneous injection of low molecular weight heparin and three months of oral dipyridamole. every 3 months the doppler screening for the occurrence of portal vein thrombus (pvt) or spleno-mesenteric thrombosis will be done for all patients. both groups will receive the therapy for one year irrespective of the doppler findings in relation to portal vein thrombus occurrence. then one year monitoring will be done in the both groups as per the primary or secondary outcome.

Eligibility criteria:
inclusion criteria: * a clinical, radiological or histologic diagnosis of cirrhosis of any etiology * splenomegaly with secondary hypersplenism, platelet count \< 50\*10\^9/l * no evidence of pvt or spleno-mesenteric thrombosis by ultrasound evaluation and angio-ct * informed consent to participate in the study exclusion criteria: * hepatocellular carcinoma or any other malignancy * hypercoagulable state other than the liver disease related * drugs- oral contraceptives, anticoagulation or anti-platelet drugs * base line inr \>2 * child-pugh grade c * recent peptic ulcer disease * history of hemorrhagic stroke * pregnancy * uncontrolled hypertension * age\>75 yrs * f2 varices with red whale marks or f3 varices * bleeding portal hypertension * human immunodeficiency virus (hiv) infection

Keywords: warfarin portal vein anticoagulants cirrhosis hypertension venous thrombosis splenectomy
an experimental study of psychological effect of school based-yoga on low-income school children

Conditions: Psychological Disturbance; Anxiety Disorder of Childhood

Summary: poverty is a common experience for many children and families in developing countries. living in a poor or low-income household has been linked to poor health and increased risk for mental health problems than the general population. previous studies link psychological well-being with yoga in adolescents and children. this study investigated the effects of a structured yoga program on psychological well-being in low-income school children.


Eligibility criteria:
inclusion criteria: * low income group * parental consent to participate in study exclusion criteria: * disabilities * substance abuse * living outside the school areas
intranasal fentanyl versus placebo for catheterization during a voiding cystourethrogram in children

Conditions: Pain

Summary: the purpose of this study is to determine whether intranasal fentanyl is better than placebo at decreasing pain in children 4-8 years of age during urinary catheterization for a vcug study.

studies have shown that the voiding cystourethrogram (vcug) can be distressful and painful for children as the child is catheterized during the procedure. currently no sedation or analgesia is recommended for the procedure. the practice of pediatrics is constantly seeking measures to decrease pain and distress for children. the opioid fentanyl was originally synthesized in the 1950's and 60's as an alternative to morphine and meperidine. the safety and efficacy of intranasal (in) fentanyl has been previously demonstrated in the setting of a pediatric emergency department. we are proposing the use of in fentanyl for analgesia prior to the catheterization for a voiding cystourethrogram (vcug). if we prove that in fentanyl is effective in reducing the pain while ensuring patient safety, it could become the analgesic of choice for this procedure.

Eligibility criteria:
inclusion criteria: 1. age 4-8 years 2. scheduled vcug at sick kids 3. understand the consent and assent form in english exclusion criteria: 1. previous adverse events to fentanyl or any opioid 2. history of a chronic respiratory or cardiac illness 3. children with developmental delay 4. children with bilateral nasal congestion.

Keywords: pediatrics pain voiding cystourethrogram catheterization fentanyl
effectiveness of respiratory muscle training with a mobile application after lobectomy

Conditions: Video Assisted Thoracic Surgery (VATS); Thoracic Surgery; Respiratory Muscle; Lung Cancer (NSCLC)

Summary: it has been observed that there are negative effects on respiratory muscle strength following lobectomy. this has led to the necessity of respiratory muscle training to mitigate these adverse effects. most studies conducted so far focus on the late postoperative period, and there are only a few studies evaluating the effectiveness of early postoperative inspiratory muscle training (imt). it is believed that this method could be useful for facilitating patient follow-up and increasing patient motivation through visual feedback.

it has been observed that there are negative effects on respiratory muscle strength following lobectomy. this has led to the necessity of respiratory muscle training to mitigate these adverse effects. most studies conducted so far focus on the late postoperative period, and there are only a few studies evaluating the effectiveness of early postoperative inspiratory muscle training (imt). additionally, there is currently no study assessing the effectiveness of imt using a smart adapter in patients who have undergone lobectomy. it is believed that this method could be useful for facilitating patient follow-up and increasing patient motivation through visual feedback. the aim of this study is to examine the changes in respiratory muscle strength and exercise capacity in patients after lobectomy via vats, comparing classical imt, mobile application-supported imt, and a control group that does not receive imt.

Eligibility criteria:
inclusion criteria: * volunteering to participate in the study, * being clinically stable, * being a lung cancer patient with a planned lobectomy with vats, * being between the ages of 18-65, * being able to cooperate with the tests to be performed. exclusion criteria: * having any orthopedic or neurological problem that prevents walking, * having undergone any surgery related to the thoracic wall, * having diseases that will affect respiratory parameters such as severe heart failure, severe chronic obstructive pulmonary disease (copd).

Keywords: lung cancer vats inspiratory muscle training
bipolar resection vs enucleation of prostate

Conditions: Benign Prostatic Hyperplasia (BPH) Requiring Surgical Resection; Benign Prostatic Hyperplasia With Outflow Obstruction; Benign Prostatic Hyperplasia With Symptomatic Lower Urinary Tract Symptoms; Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms

Summary: the aim of this study is to evaluate efficacy and safety of transurethral resection of the prostate and bipolar enucleation of the prostate.

endoscopic management of benign prostatic hyperplasia (bph), monopolar transurethral resection of the prostate (turp) has been the gold standard for many years. despite its promising efficacy in treating bph, turp is associated with a risk of significant complications and clinical limitations, including life-threatening events such as transurethral resection (tur) syndrome, as well as high cost due to long hospital stay, long catheterization time and difficulty in management of large sized prostate so alternative surgical approaches have been explored. minimally invasive approaches achieve equal efficiency to standard resection, but with a more favorable safety and less complications. anatomical enucleation of the prostate using bipolar or laser-based approaches such as holmium laser have been introduced with success and the efficacy and safety of these procedure has led to the integration into several international guidelines. early results of bipolar enucleation resemble those reported for holmium laser procedure, bipolar transurethral enucleation of the prostate was at least equally effective, and showed less complications, good hemostatic control and both shorter catheterization time and hospital stay than old standard procedure. a comparison between turp and bipolar enucleation of prostate allows us to investigate the true benefits and safety of each modality.

Eligibility criteria:
inclusion criteria: 1. patients with lower urinary tract symptoms (luts) due to bph. 2. patients with international prostate score system (ipss) more than 8. 3. patients with maximal urinary flow rate (qmax) less than 10ml/second. 4. patients with prostatic volume (60 - 100 gm). 5. patient with indication for surgical intervention. 6. patient age (50-80 years old) exclusion criteria: 1. prostatic cancer. 2. bladder cancer. 3. urethral stricture. 4. neurogenic bladder.

Keywords: turp tuep bph
alimta, carboplatin and radiation therapy for non small cell lung cancer

Conditions: Inoperable Non Small Cell Lung Cancer

Summary: to determine the safety of alimta when used with chemoradiation in inoperable non small cell lung cancer

to determine the maximal tolerated dose (mtd) and toxicities of pemetrexed (alimta) when administered concurrently with carboplatin and thoracic radiation therapy. to determine, qualitatively, the occurrence of local tumor responses identified with this regimen.

Eligibility criteria:
inclusion criteria: * unresectable stage ii, iiib or iv non small cell lung cancer. evaluable disease on planning ct scan zubrod 0-1 weight loss equal to or less than 10% 3 months prior to diagnosis fev1 greater than 1000cc adequate hematologic, renal and hepatic functions exclusion criteria: * small cell cancer stage i non small cell cancer prior chemotherapy or thoracic or lower neck radiatio therapy